Fig. 1. PSA Response, and Objective Response: Best Change in PSA Level and Target Lesions in Patients with mCRPC Treated with BAT and Nivolumab.

A Waterfall plot showing the best PSA decline from baseline for each patient (N = 45). Eighteen (N = 18) patients were observed to have a confirmed PSA decline of 50% or greater while on treatment with BAT and nivolumab. Two additional patients achieved an unconfirmed PSA₅₀ response denoted by *. B Waterfall plot showing best change in tumor volume for N = 42 evaluable patients with measureable disease. Ten (N = 10) patients achieved a 30% or greater decrease in target lesions while receiving study treatment. # indicates progressive disease as best response due to new lesions. Source data are available as a Source Data file.